Pharmaceutical companies and payers could continue to partner in the form of value-based contracting as new high-cost medicines carry the promise to treat patients with a single dose, shot or transfusion, according to an MM&M report.
The article points to Spark Therapeutics’ Luxturna and Novartis’ Kymriah, both of which entered the marketplace with performance-based pricing models. Gilead’s Yescarta followed a similar route, with more expected to follow.
“There is a tsunami of one-time therapies coming,” Spark Therapeutics’ COO John Furey said. “There are 90 in Phase III, and they are not going to go away.”